MedTrace Logo

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke

NCT06045156 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1084

Last updated 2025-12-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Tirofiban

Tirofiban is a selective glycoproteinⅡb/Ⅲa receptor inhibitor, which inhibits platelet aggregation and thrombi formation

DRUG

Tirofiban simulant

Tirofiban simulant is placebo packed the same style as tirofiban

Sponsors & Collaborators

  • The First Hospital of Jilin University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-29
Primary Completion
2026-01-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06045156 on ClinicalTrials.gov